Riskpilot← Back to searchSign inGet full accessStenblomman AB
ABActiveOrg 5566485545Stenblommans Väg 9Medical specialists activities · NACE 8622Est. 20031 employees
Revenue 2025
SEK 120K
+1233% vs 2024
EBITDA margin
-775.7%
+4% vs 2024
Equity ratio
87.2%
Financial strength
Net profit 2025
SEK 258K
-40% vs 2024
| Revenue | SEK 120K | +1233% |
| EBITDA | SEK -931K | +4% |
| Net profit | SEK 258K | -40% |
| Total assets | SEK 609K | -22% |
| Equity | SEK 531K | -7% |
| Employees | 1 | — |
Legal name
Stenblomman AB
Org number
5566485545
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
11 september 2003
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva pedagogisk, psykologisk och medicinsk verksamhet samt därmed förenlig verksamhet.
Address
Stenblommans Väg 9
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 4 | 125 | 9 | 120 |
| Staff expenses | — | −804 | −888 | −882 | −938 |
| EBITDA | −997 | −900 | −841 | −966 | −931 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −997 | −900 | −841 | −966 | −931 |
| Net financials | 1 800 | 967 | 1 163 | 1 515 | 1 263 |
| Profit before tax | 802 | 67 | 321 | 550 | 332 |
| Tax | −179 | −20 | −72 | −117 | −74 |
| Net profit | 623 | 47 | 249 | 433 | 258 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 292 | 1 085 | 532 | 783 | 609 |
| Equity | 744 | 491 | 440 | 573 | 531 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 548 | 594 | 92 | 211 | 78 |
| Total debt | 548 | 594 | 92 | 211 | 78 |
EBITDA margin
-775.7%
This company
15.8%
Market median
-5009% vs market
20212025
Equity ratio
87.2%
This company
38.2%
Market median
+128% vs market
20212025
Return on equity
48.7%
This company
18.4%
Market median
+165% vs market
20212025
Net profit margin
215.4%
This company
8.1%
Market median
+2559% vs market
20212025
Asset turnover
0.20×
This company
1.12×
Market median
-82% vs market
20212025
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SH Chief Auditor | Chief Auditor | 2022 |
| Former (1) | ||
PJ | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2020 | |
| Board of Directors | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Stenblomman AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Patrik Johan Karl Löwenadler | Audit | 0 companies |
| Sven Henrik Olsson | Chief Auditor | 0 companies |
| Åsa Heléne Bengmark | Deputy Board Member | 0 companies |
| Claes Thomas Bengmark | Board of Directors | 0 companies |